Symposium faculty to include Dmitriy
Zamarin, MD, PhD, and Alexander N.
Shoushtari, MD, medical oncologists from Memorial Sloan
Kettering Cancer Center
OSLO, Norway, Oct. 11, 2018 /PRNewswire/
-- Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard
to treat solid tumors, is hosting a Key Opinion Leader (KOL)
symposium in New York City today,
featuring two renowned immunotherapy experts from the Memorial
Sloan Kettering Cancer Center.
The meeting will consist of presentations from world leading
experts on oncolytic viruses, as well as presentations from the
Targovax senior management team. Presentations and discussion will
include an overview of oncolytic viruses in general and the
potential of this emerging technology in the treatment of cancer,
including how the engineered ONCOS adenovirus fits into the broader
landscape
The event starts at 12:00 EST /
18:00 CET.
Agenda:
12:00 – 12:10: Welcome remarks, Øystein Soug, CEO, Targovax
12:10 – 12:50: Oncolytic virus overview, Dr. Dmitriy Zamarin
12:50 – 13:30: Melanoma: the disease, CPIs, and lack of treatment
options; Early ONCOS-102 data, Dr. Alexander Shoushtari
13:30 – 13:50: Mesothelioma ORR data, Dr. Magnus Jäderberg, CMO,
Targovax
Symposium Faculty participants:
Dmitriy Zamarin, MD, PhD, Medical
Oncologist, Memorial Sloan Kettering
Dr. Zamarin's research is focused on the development of novel ways
to use the immune system to treat cancer, including evaluation of
novel immunotherapy drugs. He has published several landmark papers
on oncolytic viruses and is the Study Chair on the ONCOS-102 trial
in peritoneal cancer, in collaboration with Cancer Research
Institute (CRI), Ludwig Cancer Research and
MedImmune/AstraZeneca.
Alexander N. Shoushtari, MD,
Medical Oncologist, Memorial Sloan Kettering
Dr. Shoushtari is a renowned expert in melanoma, with a research
focus on uveal and mucosal melanomas. He has been part of several
immunotherapy trials at MSKCC and is the Principal Investigator on
the ONCOS-102 phase I trial in CPI refractory advanced
melanoma.
Drs. Zamarin and Shoushtari are both members of the research team
of Dr. Jedd Wolchok, MD, PhD, Chief,
Melanoma and Immunotherapeutics Service at the Memorial Sloan
Kettering Cancer Center.
A live webcast of the symposium will be available in the Events and
Presentations section of the Targovax website.
To register for the event, please contact
jporcelli@troutgroup.com or visit www.troutaccess.com.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting
(International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/targovax/r/targovax-key-opinion-leader-symposium-on-oncolytic-viruses-in-new-york-city-today--11-october--2018,c2641981